Total and lipid-bound serum sialic acid in children with malignancy or infections

Anticancer Research

Volumn 18, Issue 4 B, 1998, Pages 2793-2797

  Romppanen, Jarkko ^a   Petäjä, Jari ^b   Heikinheimo, Markku ^b,c   Mononen, Ilkka ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Child; LASA; Malignancy; Sensitivity; Specificity; TSA; Tumor markers

Indexed keywords

SIALIC ACID;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FOLLOW UP; HUMAN; INFANT; INFECTION; LEUKEMIA; MAJOR CLINICAL STUDY; NEUROBLASTOMA; PRIORITY JOURNAL; SOLID TUMOR; YOLK SAC TUMOR;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFECTION; LIPIDS; N-ACETYLNEURAMINIC ACID; NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0031867359     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Yogeeswaran G: Cell surface glycolipids and glycoproteins in malignant transformation. Adv Cancer Res 38: 289-350, 1983.
2. Seider A, Graf N, Sitzmann F: Wertigkeit der sialinsäurebestimmung im serum bei kindern. Pädiatrie und Pädologie 27: 43-46, 1992.
3. Patel PS, Adhvaryu SG, Balar DB: Serum glycoconjugates in patients with anemia and myeloid leukemia. Tumori 74: 639-644, 1988.
4. Patel PS, Adhvaryu SG, Baxi BR: Tumor markers in leukemia: evaluation of serum levels of different forms of sialic acid, Regan isoenzyme and lactate dehydrogenase. Int J Biol Markers 6: 177-182, 1991.
5. O'Kennedy R, Berns G, Moran E, Smyth H, Carroll K, Thornes RD, O'Brien A, Fennelly J, Butler M: A critical analysis of the use of sialic acid determination in the diagnosis of malignancy. Cancer Lett 58: 91-100, 1991.
6. Shamberger RJ: Serum sialic acid in normals and in cancer patients. J Clin Chem Clin Biochem 22: 647-651, 1984.
7. Voigtmann R, Pokorny J, Meinshausen A: Evaluation and limitations of the lipid-associated sialic acid test for the detection of human cancer. Cancer 64: 2279-2283, 1989.
8. Plucinsky MC, Riley WM, Prorok JJ, Alhadeff JA: Total and lipid-associated serum sialic acid levels in cancer patients with different primary sites and differing degrees of metastatic involvement. Cancer 58: 2680-2685, 1986.
9. Romppanen J, Eskelinen M, Tikanoja S, Mononen I: Total and lipid-bound serum sialic acid in benign and malignant breast disease. Anticancer Res 17: 1249-1254, 1997.
10. Patel PS, Adhvaryu SG, Balar DB, Parikh BJ, Shah PM: Clinical application of serum levels of sialic acid, fucose and seromucoid fraction as tumour markers in human leukemias. Anticancer Res 14: 747-752, 1994.
11. Schutter EMJ, Visser JJ, van Kamp GJ, Mensdorff-Pouilly S, van Dijk W, Hilgers J, Kenemans P: The utility of lipid-associated sialic acid (LASA or LSA) as a serum marker for malignancy. A review of the literature. Tumour Biol 13: 121-132, 1992.
12. Dnistrian AM, Schwartz MK: Plasma lipid-bound sialic acid and carcinoembryonic antigen in cancer patients. Clin Chem 27: 1737-1739, 1981.
13. Stefenelli N, Klotz H, Engel A, Bauer P: Serum sialic acid in malignant tumors, bacterial infections, and chronic liver diseases. J Cancer Res Clin Oncol 109: 55-59, 1985.
14. van Dijk W, Pos O, van der Stell ME, Moshage HJ, Yap SH, Dente L, Baumann P, Eap CB: Inflammation-induced changes in expression and glycosylation of genetic variants of α1-acid glycoprotein. Studies with human sera, primary cultures of human hepatocytes and transgenic mice. Biochem J 276: 343-347, 1991.
15. Shukla AK, Schauer R: Analysis of N,O-acylated neuraminic acids by high-performance liquid anion-exchange chromatography. J Chromatogr 244: 81-89, 1982.
16. Katopodis N, Stock CC: Improved method to determine lipid bound sialic acid in plasma or serum. Res Commun Chem Pathol Pharmacol 30: 171-180, 1980.
17. Youden D: Index for rating diagnostic tests. Cancer 3: 32-35, 1950.
18. Warren L, Fuhrer JP, Buck CA: Surface glycoproteins of normal and transformed cells: A difference determined by sialic acid and a growth-dependent sialyl transferase. Proc Natl Acad Sci USA 69: 1838-1842, 1972.
19. Brockhausen I, Yang J-M, Burchell J, Whitehouse C, Taylor-Papadimitriou J: Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur J Biochem 235: 607-617, 1995.
20. Thampoe IJ, Furakawa K, Vellve E, Lloyd KO: Sialyltransferase levels and ganglioside expression in melanoma and other cultured human cancer cells. Cancer Res 49: 6258-6264, 1989.
21. Rossowski W, Srivastava SBI: Glycosyltransferase activities in leukemic cells from patients and human leukemic cell lines. Eur J Cancer Clin Oncol 19: 1431-1437, 1983.
22. Kanani A, Sutherland RD, Fibach E, Matta KL, Hindenburg A, Brockhausen I, Kuhns W, Taub RN, van den Eijnden DH, Baker MA: Human leukemic myeloblasts and myeloblastoid cells contain the enzyme cytidine 5'-monophosphate-N-acetylneuraminic acid: zGalß1-3GalNAcα(2-3)-sialyltransferase. Cancer Res 50: 5003-5007, 1990.
23. Baker MA, Kanani A, Brockhausen I, Schachter H, Hindenburg A, Taub RN: Presence of cytidine 5'-monophospho-N-acetylneuraminic acid:Galß1-3GalNAc-R α(2-3)-sialyltransferase in normal human leukocytes and increased activity of this enzyme in granulocytes from chronic myelogenous leukemia patients. Cancer Res 47: 2763-2766, 1987.